Intellia Therapeutics (NASDAQ:NTLA) Reaches New 1-Year Low – Time to Sell?

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) reached a new 52-week low on Tuesday . The company traded as low as $9.21 and last traded at $9.35, with a volume of 302791 shares trading hands. The stock had previously closed at $9.58.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on NTLA. Wedbush reissued a “neutral” rating and issued a $10.00 target price (down from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. William Blair reaffirmed a “neutral” rating and issued a $14.00 target price on shares of Intellia Therapeutics in a report on Monday, November 18th. Morgan Stanley cut Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $56.00 to $11.00 in a report on Monday, January 27th. BMO Capital Markets cut their target price on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research report on Friday, January 10th. Finally, The Goldman Sachs Group dropped their price target on Intellia Therapeutics from $19.00 to $12.00 and set a “neutral” rating for the company in a research note on Tuesday, January 14th. One analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $48.71.

Intellia Therapeutics Stock Performance

The stock has a fifty day moving average price of $11.74 and a 200 day moving average price of $16.93. The stock has a market cap of $940.08 million, a PE ratio of -1.69 and a beta of 1.80.

Insider Buying and Selling at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 29,000 shares of company stock worth $352,551 over the last quarter. Insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

A number of large investors have recently bought and sold shares of the business. Whipplewood Advisors LLC bought a new position in shares of Intellia Therapeutics in the 4th quarter worth $40,000. Eastern Bank bought a new position in Intellia Therapeutics in the third quarter worth about $41,000. Jones Financial Companies Lllp boosted its holdings in shares of Intellia Therapeutics by 140.9% in the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock valued at $45,000 after buying an additional 2,280 shares in the last quarter. Values First Advisors Inc. purchased a new stake in Intellia Therapeutics during the third quarter valued at approximately $54,000. Finally, Daiwa Securities Group Inc. boosted its stake in Intellia Therapeutics by 80.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company’s stock valued at $60,000 after acquiring an additional 2,299 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.